A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

被引:18
|
作者
He, Xiaofeng [1 ,2 ]
Su, Jiao [3 ]
Ma, Yu'nan [1 ]
Zhang, Wenping [4 ]
Tang, Shixing [1 ,5 ]
机构
[1] Southern Med Univ, Sch Publ Hlth, Dept Epidemiol, Guangzhou, Peoples R China
[2] Changzhi Med Coll, Inst Evidence Based Med, Heping Hosp, Changzhi, Peoples R China
[3] Changzhi Med Coll, Dept Biochem, Changzhi, Peoples R China
[4] Changzhi Med Coll, Dept Cardiothorac Surg, Heping Hosp, Changzhi, Peoples R China
[5] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
COVID-19; vaccine; efficacy; effectiveness; breakthrough infection; COVID-19-ASSOCIATED EMERGENCY-DEPARTMENT; URGENT CARE ENCOUNTERS; VARIANT PREDOMINANCE; SARS-COV-2; DELTA; INTERIM ANALYSIS; CHADOX1; NCOV-19; PFIZER-BIONTECH; VISION NETWORK; HEALTH SYSTEM; STATES;
D O I
10.3389/fimmu.2022.945930
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
It is urgently needed to update the comprehensive analysis about the efficacy or effectiveness of COVID-19 vaccines especially during the COVID-19 pandemic caused by SARS-CoV-2 Delta and Omicron variants. In general, the current COVID-19 vaccines showed a cumulative efficacy of 66.4%, 79.7%, and 93.6% to prevent SARS-CoV-2 infection, symptomatic COVID-19, and severe COVID-19, respectively, but could not prevent the asymptomatic infection of SARS-CoV-2. Furthermore, the current COVID-19 vaccines could effectively prevent COVID-19 caused by the Delta variant although the incidence of breakthrough infection of the SARS-CoV-2 Delta variant increased when the intervals post full vaccination extended, suggesting the waning effectiveness of COVID-19 vaccines. In addition, one-dose booster immunization showed an effectiveness of 74.5% to prevent COVID-19 caused by the Delta variant. However, current COVID-19 vaccines could not prevent the infection of Omicron sub-lineage BA.1.1.529 and had about 50% effectiveness to prevent COVID-19 caused by Omicron sub-lineage BA.1.1.529. Furthermore, the effectiveness was 87.6% and 90.1% to prevent severe COVID-19 and COVID-19-related death caused by Omicron sub-lineage BA.2, respectively, while one-dose booster immunization could enhance the effectiveness of COVID-19 vaccines to prevent the infection and COVID-19 caused by Omicron sub-lineage BA.1.1.529 and sub-lineage BA.2. Two-dose booster immunization showed an increased effectiveness of 81.8% against severe COVID-19 caused by the Omicron sub-lineage BA.1.1.529 variant compared with one-dose booster immunization. The effectiveness of the booster immunization with RNA-based vaccine BNT162b2 or mRNA-1273 was over 75% against severe COVID-19 more than 17 weeks after booster immunization whereas the heterogenous booster immunization showed better effectiveness than homologous booster immunization. In summary, the current COVID-19 vaccines could effectively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization could enhance protection capability, and two-dose booster immunization could provide additional protection against severe COVID-19.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
    Cai, Changjing
    Peng, Yinghui
    Shen, Edward
    Huang, Qiaoqiao
    Chen, Yihong
    Liu, Ping
    Guo, Cao
    Feng, Ziyang
    Gao, Le
    Zhang, Xiangyang
    Gao, Yan
    Liu, Yihan
    Han, Ying
    Zeng, Shan
    Shen, Hong
    [J]. MOLECULAR THERAPY, 2021, 29 (09) : 2794 - 2805
  • [2] Effectiveness of COVID-19 vaccines
    Syed, Mohamed Ahmed
    Abdulla, Hamda
    Alnuaimi, Ahmed Sameer
    [J]. JOURNAL OF INFECTION, 2022, 84 (06) : E118 - E119
  • [3] Efficacy and effectiveness of COVID-19 vaccines in Africa: A systematic review
    Raji, Tajudeen
    Fallah, Mosoka Papa
    Dereje, Nebiyu
    Kakooza, Francis
    Ndembi, Nicaise
    Abdulaziz, Mohammed
    Aragaw, Merawi
    Kaseya, Jean
    Ngongo, Alain Ngashi
    [J]. PLOS ONE, 2024, 19 (06):
  • [4] Efficacy of COVID-19 vaccines
    Saadh, Mohamed J.
    Jaber, Saif Aldeen
    [J]. MICROBIAL PATHOGENESIS, 2022, 171
  • [6] COVID-19 Vaccines: A Comprehensive Overview
    Soni, Akshita
    Lodha, Rakesh
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2022, 89 (11): : 1165 - 1165
  • [7] Waning effectiveness of COVID-19 vaccines
    Chemaitelly, Hiam
    Abu-Raddad, Laith J.
    [J]. LANCET, 2022, 399 (10327): : 771 - 773
  • [8] COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants
    Selvam, Suganya Panneer
    Ramani, Pratibha
    Ramya, R.
    Sundar, Sandhya
    Lakshmi, T. A.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (05)
  • [9] Efficacy and safety of COVID-19 vaccines
    Grana, Carolina
    Ghosn, Lina
    Evrenoglou, Theodoros
    Jarde, Alexander
    Minozzi, Silvia
    Bergman, Hanna
    Buckley, Brian S.
    Probyn, Katrin
    Villanueva, Gemma
    Henschke, Nicholas
    Bonnet, Hillary
    Assi, Rouba
    Menon, Sonia
    Marti, Melanie
    Devane, Declan
    Mallon, Patrick
    Lelievre, Jean-Daniel
    Askie, Lisa M.
    Kredo, Tamara
    Ferrand, Gabriel
    Davidson, Mauricia
    Riveros, Carolina
    Tovey, David
    Meerpohl, Joerg J.
    Grasselli, Giacomo
    Rada, Gabriel
    Hrobjartsson, Asbjorn
    Ravaud, Philippe
    Chaimani, Anna
    Boutron, Isabelle
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (12):
  • [10] COVID-19 VACCINES-A Comprehensive OVERVIEW
    Srinivasan, S.
    [J]. INDIAN PEDIATRICS, 2022, 59 (06) : 508 - 508